Interpreting TRIPS : globalisation of intellectual property rights and access to medicines /
"Protection of intellectual property rights (IPRs) has become a global issue. The Trade-Related Aspects of Intellectual Property (TRIPS) Agreement outlines the minimum standards for IPR protection for WTO members and offers a global regime for IPR protection. However, the benefits of TRIPS are...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Libro |
| Lenguaje: | Inglés |
| Publicado: |
Oxford, UK ; Portland, Or. :
Hart,
2011.
|
| Materias: | |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 04918cam a2200421 a 4500 | ||
|---|---|---|---|
| 001 | 99700426204151 | ||
| 005 | 20180426125253.0 | ||
| 008 | 110721s2011 enk b 001 0 eng | ||
| 010 | |a 2011290433 | ||
| 015 | |a GBB070815 |2 bnb | ||
| 016 | 7 | |a 101579697 |2 DNLM | |
| 016 | 7 | |a 015572813 |2 Uk | |
| 020 | |a 9781841139531 |q (hbk.) | ||
| 020 | |a 184113953X |q (hbk.) | ||
| 035 | |a (OCoLC)607975204 |z (OCoLC)712779602 | ||
| 035 | |a (OCoLC)ocn607975204 | ||
| 040 | |a UKM |c NLM |d UKM |d DLC |d BTCTA |d YDXCP |d ILI |d NLE |d WCL |d TKF |d CDX |d BWK |d BWX |d PUL |d DEBBG |d I8H |d OCLCF |d BEDGE |d OCLCQ |d OCLCO |d OCLCQ |d IOD |d UX0 |d UKUOY |d NLM |d OCLCO |d DHA |d OCLCA |d OCLCQ |d U@S | ||
| 042 | |a pcc | ||
| 049 | |a U@SA | ||
| 050 | 0 | 0 | |a K1401.A4 1994 |b Y36 2011 |
| 082 | 0 | 4 | |a 346.048 |2 22 |
| 100 | 1 | |a Yamane, Hiroko. | |
| 245 | 1 | 0 | |a Interpreting TRIPS : |b globalisation of intellectual property rights and access to medicines / |c Hiroko Yamane. |
| 246 | 3 | |a Interpreting Agreement on Trade-Related Intellectual Property Rights | |
| 246 | 3 | 0 | |a Globalisation of intellectual property rights and access to medicines |
| 260 | |a Oxford, UK ; |a Portland, Or. : |b Hart, |c 2011. | ||
| 300 | |a xlvi, 535 p. ; |c 25 cm. | ||
| 504 | |a Incluye referencias bibliográficas e índice. | ||
| 505 | 0 | |a Introduction -- Part I. Background: 1. Innovation Incentives ; 2. International IP Cooperation and Developing Country Perspectives ; 3. Biotech Inventions and Patentable Subject Matter -- Part II. The TRIPS Agreement: 4. Uruguay Round Negotiations and the Adoption of TRIPS ; 5. The TRIPS Agreement de Lege Lata: the outline ; 6. Various Methods of Interpretation: WTO Agreements and the Vienna Convention on the Law of Treaties ; 7. TRIPS Provisions as Interpreted by the WTO Dispute Settlement Organs -- Part III. Access to Medicines: 8. T he AIDS Epidemic and TRIPS ; 9. Doha Declaration and Beyond -- Part IV. IP and Industrial Policies: 10. Emerging Economiesʹ IP and Industrial Policies ; 11. Pharmaceutical Industries, R&D and Public Health in Emerging Economies -- Part V. TRIPS Flexibilities and National Implementation: 12. TRIPS Flexibilities and National Implementation (1) Patentable Subject Matter and Patentability Requirements ; 13. TRIPS Flexibilities and National Implementation (2) Protection of Test Data Submitted to Regulatory Authorities ; 14. ʹTRIPS Plusʹ Provisions in US Free Trade Agreements -- Part VI. Interpreting TRIPS for Innovation: 15. Recasting the Debate on Intellectual Property Rights. | |
| 520 | |a "Protection of intellectual property rights (IPRs) has become a global issue. The Trade-Related Aspects of Intellectual Property (TRIPS) Agreement outlines the minimum standards for IPR protection for WTO members and offers a global regime for IPR protection. However, the benefits of TRIPS are more questionable in poorer countries where national infrastructure for research and development (R&D) and social protection are inadequate, whereas the cost of innovation is high. Today, after more than a decade of intense debate over global IPR protection, the problems remain acute, although there is also evidence of progress and cooperation. This book examines various views of the role of IPRs as incentives for innovation against the backdrop of development and the transfer of technology between globalised, knowledge-based, high technology economies. The book retraces the origins, content and interpretations of the TRIPS Agreement, including its interpretations by WTO dispute settlement organs. It also analyses sources of controversy over IPRs, examining pharmaceutical industry strategies of emerging countries with different IPR policies. The continuing international debate over IPRs is examined in depth, as are TRIPS rules and the controversy about implementing the 'flexibilities' of the Agreement in the light of national policy objectives. The author concludes that for governments in developing countries, as well as for their business and scientific communities, a great deal depends on domestic policy objectives and their implementation. IPR protection should be supporting domestic policies for innovation and investment. This, in turn requires a re-casting of the debate about TRIPS, to place cooperation in global and efficient R&D at the heart of concerns over IPR protection." --Descripción del editor. | ||
| 630 | 0 | 0 | |a Agreement on Trade-Related Aspects of Intellectual Property Rights |d (1994 April 15) |
| 630 | 0 | 7 | |a Acuerdo sobre los Aspectos de los Derechos de Propiedad Intelectual Relacionados con el Comercio |d (1994 Abril 15) |2 UDESA |
| 650 | 0 | |a Intellectual property (International law) | |
| 650 | 0 | |a Intellectual property (International law) |x Economic aspects. | |
| 650 | 0 | |a Pharmaceutical industry. | |
| 650 | 7 | |a Propiedad intelectual (Derecho internacional) |2 UDESA | |
| 650 | 7 | |a Propiedad intelectual (Derecho internacional) |x Aspectos económicos. |2 UDESA | |
| 650 | 7 | |a Industria farmacéutica. |2 UDESA | |